Circulating Tumor Cells in Early Breast Cancer: A 10-Year Follow-Up Update

Area of Science:

• Oncology
• Cancer Biology
• Clinical Diagnostics

Background:

• Circulating tumor cells (CTCs) are key to metastasis in solid tumors.
• Prognostic value of CTCs is established in metastatic breast cancer (BC), but uncertain in early stages.
• This study evaluates the 10-year prognostic significance of CTC detection in early-stage BC.

Purpose of the Study:

• To assess the long-term prognostic value of circulating tumor cells (CTCs) in early-stage breast cancer (BC).
• To determine if CTC detection pre- and post-surgery predicts disease-free survival (DFS) over 10 years.

Main Methods:

• A cohort of 48 patients with stage I-II operable BC was analyzed.
• CTCs were isolated using an EpCAM-independent method and DEPArray analysis pre-surgery and six months post-surgery.
• Disease-free survival (DFS) was assessed over 10 years using Kaplan-Meier estimates and log-rank tests.

Main Results:

• No statistically significant association was found between CTC presence and 10-year DFS (p=0.13 pre-surgery, p=0.25 post-surgery).
• Only 3 patients (6.3%) experienced disease relapse; 2 developed lymphomas.
• CTC detection did not reliably predict long-term outcomes in this cohort.

Conclusions:

• Circulating tumor cell (CTC) enumeration is not a reliable prognostic marker for long-term DFS in early-stage breast cancer.
• Methodological challenges and cost limit the role of CTC analysis in early BC.
• Larger, standardized studies are required to validate the prognostic relevance of CTCs in early BC.